Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercoagulability in heart failure

S M Jafri1

  • 1Division of Cardiovascular Medicine, Henry Ford Hospital, Detroit, Michigan 48202, USA.

Seminars in Thrombosis and Hemostasis
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dietary practices and beliefs of patients with chronic liver disease.

JPMA. The Journal of the Pakistan Medical Association·2000
Same author

Racial differences in patients with heart failure.

Clinical cardiology·2000
Same author

Unfractionated heparin is the heparin of choice in the management of patients with acute coronary syndromes.

Journal of thrombosis and thrombolysis·1999
Same author

Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure.

Progress in cardiovascular diseases·1999
Same author

Usefulness of exercise echocardiography in predicting cardiac events in an outpatient population.

The American journal of cardiology·1998
Same author

Role of antiarrhythmic agents after myocardial infarction with special reference to the EMIAT and CAMIAT trials of amiodarone. European Myocardial Infarct Amiodarone Trial. Canadian Amiodarone Myocardial Infarction Trial.

Progress in cardiovascular diseases·1998
Same journal

Full- vs Reduced-Dose Direct Oral Anticoagulants for Extended Treatment of Cancer-Associated Thrombosis: A Multicenter Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Too Old for PESI?: Risk Stratification of Octogenarians with Pulmonary Embolism in the Emergency Department.

Seminars in thrombosis and hemostasis·2026
Same journal

Acute Management and Bleeding Outcomes in Pediatric Pulmonary Embolism: A Large Single-Center Retrospective Cohort Study.

Seminars in thrombosis and hemostasis·2026
Same journal

Red Blood Cells in Hemostasis and Thrombosis: Mechanisms, Interactions, and Clinical Implications.

Seminars in thrombosis and hemostasis·2026
Same journal

Pediatric Pulmonary Infarction and Infarction-Like Pulmonary Injury: An Etiology-Oriented Narrative Review.

Seminars in thrombosis and hemostasis·2026
Same journal

Comparison of the Coagulation Profile Following Treatment of Major Surgical Haemorrhage with Fresh Frozen Plasma or Fibrinogen Concentrate.

Seminars in thrombosis and hemostasis·2026
See all related articles

Heart failure patients show increased platelet activation and blood clotting, raising thromboembolism risk. Therapies targeting these factors may reduce heart failure complications and mortality.

Area of Science:

  • Cardiology
  • Hematology
  • Thrombosis Research

Background:

  • Thromboembolism is a significant complication in heart failure (HF).
  • HF involves vascular pathology, hypercoagulability, and impaired blood flow, predisposing to thrombosis.
  • Understanding platelet function and coagulation is crucial for managing HF complications.

Purpose of the Study:

  • To review and summarize data on platelet function and coagulation indices in heart failure patients.
  • To highlight the prothrombotic state associated with heart failure.
  • To explore the potential therapeutic implications of targeting platelet activation and hypercoagulability.

Main Methods:

  • Review of existing studies on platelet function markers in heart failure.
  • Analysis of coagulation indices and fibrinolytic products in heart failure patients.

Related Experiment Videos

  • Synthesis of data on plasma concentrations of specific biomarkers.

    • Main Results:

    • Elevated plasma concentrations of beta-thromboglobulin (a marker of platelet activation) observed in HF patients.
    • Increased plasma levels of fibrinopeptide A and evidence of thrombin activation in HF.
    • Higher concentrations of endothelial procoagulants, von Willebrand factor, fibrinolytic products, and D-dimer in heart failure.

    Conclusions:

    • Platelet activation and hypercoagulability are prevalent in heart failure.
    • These hemostatic abnormalities may serve as surrogates for clinical thrombotic events.
    • Antiplatelet or anticoagulant therapies hold potential for reducing thromboembolism and mortality in heart failure.